- Lanz, Tobias V;
- Brewer, R Camille;
- Ho, Peggy P;
- Moon, Jae-Seung;
- Jude, Kevin M;
- Fernandez, Daniel;
- Fernandes, Ricardo A;
- Gomez, Alejandro M;
- Nadj, Gabriel-Stefan;
- Bartley, Christopher M;
- Schubert, Ryan D;
- Hawes, Isobel A;
- Vazquez, Sara E;
- Iyer, Manasi;
- Zuchero, J Bradley;
- Teegen, Bianca;
- Dunn, Jeffrey E;
- Lock, Christopher B;
- Kipp, Lucas B;
- Cotham, Victoria C;
- Ueberheide, Beatrix M;
- Aftab, Blake T;
- Anderson, Mark S;
- DeRisi, Joseph L;
- Wilson, Michael R;
- Bashford-Rogers, Rachael JM;
- Platten, Michael;
- Garcia, K Christopher;
- Steinman, Lawrence;
- Robinson, William H
Multiple sclerosis (MS) is a heterogenous autoimmune disease in which autoreactive lymphocytes attack the myelin sheath of the central nervous system. B lymphocytes in the cerebrospinal fluid (CSF) of patients with MS contribute to inflammation and secrete oligoclonal immunoglobulins1,2. Epstein-Barr virus (EBV) infection has been epidemiologically linked to MS, but its pathological role remains unclear3. Here we demonstrate high-affinity molecular mimicry between the EBV transcription factor EBV nuclear antigen 1 (EBNA1) and the central nervous system protein glial cell adhesion molecule (GlialCAM) and provide structural and in vivo functional evidence for its relevance. A cross-reactive CSF-derived antibody was initially identified by single-cell sequencing of the paired-chain B cell repertoire of MS blood and CSF, followed by protein microarray-based testing of recombinantly expressed CSF-derived antibodies against MS-associated viruses. Sequence analysis, affinity measurements and the crystal structure of the EBNA1-peptide epitope in complex with the autoreactive Fab fragment enabled tracking of the development of the naive EBNA1-restricted antibody to a mature EBNA1-GlialCAM cross-reactive antibody. Molecular mimicry is facilitated by a post-translational modification of GlialCAM. EBNA1 immunization exacerbates disease in a mouse model of MS, and anti-EBNA1 and anti-GlialCAM antibodies are prevalent in patients with MS. Our results provide a mechanistic link for the association between MS and EBV and could guide the development of new MS therapies.